Design Therapeutics Inc News - DSGN

Empower your portfolio: Real-time discussions and actionable trading ideas.

FeaturedAnimoca Brands leads Hivello funding round ahead of Token Listing

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Design Therapeutics Tanks Even After Positive Clinical Data

Shares of Design Therapeutics (NASDAQ: DSGN) tanked more than 20% in pre-market trading on Thursday even as the clinical-stage biotechnology...

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with...

Current Report Filing (8-k)

0001807120false00018071202022-11-032022-11-03 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 ...

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported...

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

CARLSBAD, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a...

DSGN under $5

👍️0

Monksdream 9 months ago

DSGN under $5

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Design Therapeutics Inc (DSGN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

DSGN News

FeaturedAnimoca Brands leads Hivello funding round ahead of Token Listing

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Design Therapeutics Tanks Even After Positive Clinical Data

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Current Report Filing (8-k)

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Statement of Ownership (sc 13g)

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

RBC Capital Sticks to Its Buy Rating for Design Therapeutics (DSGN)

SVB Securities Sticks to Its Buy Rating for Design Therapeutics (DSGN)

Quarterly Report (10-q)

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

DSGN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Design Therapeutics Inc (DSGN) News

Design Therapeutics Inc (DSGN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

DSGN News

FeaturedAnimoca Brands leads Hivello funding round ahead of Token Listing

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Design Therapeutics Tanks Even After Positive Clinical Data

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Current Report Filing (8-k)

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Statement of Ownership (sc 13g)

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

RBC Capital Sticks to Its Buy Rating for Design Therapeutics (DSGN)

SVB Securities Sticks to Its Buy Rating for Design Therapeutics (DSGN)

Quarterly Report (10-q)

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

DSGN Discussion

Your Recent History

Go Ad-Free